Intravitreal anti-VEGF yields significant benefit in treatment of stage 3+ ROP

Hasson, Matt
May 2011
Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p30
Academic Journal
The article discusses research on the effect of intravitreal bevacizumab treatment on patients with stage 3 acute retinopathy of prematurity, published in the 2011 issue of the "New England Journal of Medicine."


Related Articles

  • Anti-VEGF therapy superior to laser for preventing recurrences of retinopathy of prematurity. KUZNAR, WAYNE // Contemporary Pediatrics;Mar2011, Vol. 28 Issue 3, p14 

    No abstract available.

  • Round table: Are physicians ready to adopt intravitreal bevacizumab as routine treatment for ROP?  // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p32 

    An excerpt from a round table discussion conducted at the 2011 American Association for Pediatric Ophthalmology and Stabismus (AAPOS) which focused on the efficacy of intravitreal bevacizumab in treating retinopathy is presented.

  • Physicians consider adopting intravitreal bevacizumab as routine treatment for ROP.  // Ocular Surgery News;5/25/2011, Vol. 29 Issue 10, p1 

    The article discusses a debate among U.S. physicians regarding the potential adoption of intravitreal bevacizumab as retinopathy of prematurity (ROP) treatment in 2011.

  • Anti-VEGF treatment for acute ROP - not yet recommended! Gilbert, Clare // Community Eye Health Journal;2014, Vol. 27 Issue 87, p46 

    The author cites several reasons why anti-vascular endothelial growth factor (VEGF) drugs are not recommended for severe retinopathy of prematurity (ROP) including the effectiveness in preventing early recurrence and major concerns about the short and long-term impact of anti-VEGF on babies.

  • [Commentary on] Anti-VEGF therapy may be an option for stage 3, zone 1 ROP. Chan, R. V. Paul // Ocular Surgery News;10/10/2010, Vol. 28 Issue 19, p20 

    The article discusses research study done on the potential role of intravitreal anti-vascular endothelial growth factor (VEGF) therapy in the treatment of zone 1 retinopathy of prematurity, presented by Doctor Khaled A. Tawansy at the American Society of Retina Specialists meeting from August 28...

  • Anti-VEGF Agents for Ocular Angiogenesis and Vascular Permeability. Kimoto, Kenichi; Kubota, Toshiaki // Journal of Ophthalmology;2012, p1 

    We review articles describing intravitreal injection of anti-VEGF drug trials, while discussing the mechanisms of the action of anti- VEGF antibodies, and also evaluating their outcomes. Intraocular injections of anti-VEGF drug are considered to be an effective treatment for macular edema after...

  • All ophthalmologists should be familiar with ROP and its treatments. Lindstrom, Richard L. // Ocular Surgery News;1/25/2012, Vol. 30 Issue 2, p3 

    The author asserts that all ophthalmologists must be familiar with retinopathy of prematurity (ROP) and its treatments. He says that many factors other than well-managed oxygen therapy play a role in ROP development. He adds that management by experts is ideal, which is often a vitreoretinal...

  • Close follow-up recommended for posterior ischemic ROP treated with anti-VEGF. Pagnani, Michelle // Ocular Surgery News;9/25/2011, Vol. 29 Issue 18, p21 

    The article reports on a study regarding the use of anti-vascular endothelial growth factor (VEGF) therapy in infants with posterior ischemic retinopathy of prematurity (ROP), presented by researcher Amin Kherani at the 2011 Meeting of the American Society of Retina Specialists (ASRS).

  • Neonatal Hyperglycemia Inhibits Angiogenesis and Induces Inflammation and Neuronal Degeneration in the Retina. Kermorvant-Duchemin, Elsa; Pinel, Alexis Christophe; Lavalette, Sophie; Lenne, Delphine; Raoul, William; Calippe, Bertrand; Behar-Cohen, Francine; Sahel, José-Alain; Guillonneau, Xavier; Sennlaub, Florian // PLoS ONE;Nov2013, Vol. 8 Issue 11, p1 

    Recent evidence suggests that transient hyperglycemia in extremely low birth weight infants is strongly associated with the occurrence of retinopathy of prematurity (ROP). We propose a new model of Neonatal Hyperglycemia-induced Retinopathy (NHIR) that mimics many aspects of retinopathy of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics